Patents by Inventor Mahendra G. Dedhiya

Mahendra G. Dedhiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100286260
    Abstract: The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods of treating conditions by administering the formulations are also described.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 11, 2010
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Mahendra G. Dedhiya, Anil Chhettry, Yan Yang, Yun Mo, Bhaveshkumar H. Kothari
  • Publication number: 20100216745
    Abstract: The present invention relates to new cephem compounds useful for the treatment of bacterial infections. The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 26, 2010
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Mahendra G. Dedhiya, Brahma N. Singh
  • Publication number: 20100197797
    Abstract: The present invention relates to compositions comprising milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride) and methods for managing fibromyalgia comprising administering milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride). The present invention also relates to titration packs comprising dosage forms (e.g., tablets) comprising milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride) for oral administration. The titration packs enable patient compliance with a regime of changing dosage of the milnacipran or pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride).
    Type: Application
    Filed: February 5, 2010
    Publication date: August 5, 2010
    Inventors: Srinivas G. Rao, Michael R. Gendreau, Mahendra G. Dedhiya
  • Publication number: 20100035995
    Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.
    Type: Application
    Filed: October 14, 2009
    Publication date: February 11, 2010
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Mahendra G. Dedhiya, Shashank Mahashabde, Yan Yang, Anshu Goel, Erhard Seiller, Bernhard Hauptmeier
  • Publication number: 20100028427
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Application
    Filed: March 24, 2009
    Publication date: February 4, 2010
    Applicant: Forest Laboratories, Inc.
    Inventors: Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
  • Publication number: 20100016334
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Application
    Filed: July 16, 2009
    Publication date: January 21, 2010
    Inventors: Ranajoy SARKAR, Mahendra G. DEDHIYA, Anil CHHETTRY
  • Patent number: 7648696
    Abstract: A stable composition for rapid delivery by inhalation to the lungs, and subsequently to the bloodstream, is provided. The composition comprises a therapeutically effective amount of delta-9-tetrahydrocannabinol in a pharmaceutically-acceptable semiaqueous solvent comprising an alcohol, water and a glycol. A composition comprising volumetric ratios of ethanol:water:propylene glycol selected from those in the range of from 10-70:10-30:20-80, respectively, having a combined total of 100 is also provided. A sterile and/or preserved sealed unit-or multi-unit dosage form of delta-9-tetrahydrocannabinol is further provided.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: January 19, 2010
    Assignee: Unimed Pharmaceuticals, LLC
    Inventors: Andrea M McPhillips, Julia J Economou, Mahendra G Dedhiya, Beverly Ann Wynne
  • Publication number: 20090247644
    Abstract: The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.
    Type: Application
    Filed: March 27, 2009
    Publication date: October 1, 2009
    Inventors: Mahendra G. DEDHIYA, Ranajoy SARKAR
  • Publication number: 20080194638
    Abstract: The present invention relates to bioavailable pharmaceutical formulations of heterocyclic compounds, such as such as N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide (oglemilast) and pharmaceutically acceptable salts thereof, to processes for their preparation and to methods of treatment using the same. The present invention also relates to substantially pure amorphous forms of heterocyclic compounds, such as oglemilast. The invention is particularly directed to bioavailable pharmaceutical oral dosage forms containing amorphous oglemilast.
    Type: Application
    Filed: February 8, 2008
    Publication date: August 14, 2008
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Mahendra G. DEDHIYA, Rahul Surana, Suneel K. Rastogi, Anil Chhetrry
  • Publication number: 20040162336
    Abstract: A stable composition for rapid delivery by inhalation to the lungs, and subsequently to the bloodstream, is provided. The composition comprises a therapeutically effective amount of delta-9-tetrahydrocannabinol in a pharmaceutically-acceptable semiaqueous solvent comprising an alcohol, water and a glycol. A composition comprising volumetric ratios of ethanol:water:propylene glycol selected from those in the range of from 10-70:10-30:20-80, respectively, having a combined total of 100 is also provided. A sterile and/or preserved sealed unit-or multi-unit dosage form of delta-9-tetrahydrocannabinol is further provided.
    Type: Application
    Filed: September 5, 2003
    Publication date: August 19, 2004
    Inventors: Andrea M. McPhillips, Julia J. Economou, Mahendra G. Dedhiya, Beverley Ann Wynne
  • Patent number: 6747058
    Abstract: A formulation of delta-9-tetrahydrocannabinol in a semi-aqueous solvent, such as 35:10:55 alcohol:water:propylene glycol (v/v), produces a stable clear solution near the solubility point of the drug. Because delta-9-tetrahydrocannabinol has poor affinity for the formulation, it is able to partition out and transport across cell membranes to reach the bloodstream quickly. This has been demonstrated by the comparative tmax values achieved in single dose intravenous and 14 day multiple dose inhalation studies conducted in dogs and rats.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: June 8, 2004
    Assignee: Unimed Pharmaceuticals, Inc.
    Inventors: Mahendra G. Dedhiya, Julia J. Economou, Andrea M. McPhillips, Beverley A. Wynne